Literature DB >> 6122771

Human plasmacytoma with an unusual karyotype growing in vitro and producing light-chain immunoglobulin.

A Karpas, P Fisher, D Swirsky.   

Abstract

A new human plasmacytoma line (Karpas 707) was established from the cells of the bone-marrow and peripheral blood of a patient with Bence-Jones-positive multiple myeloma. The cells of this line resembled the patient's malignant cells and fresh myeloma cells from nine other patients in being Epstein-Barr viral nuclear antigen negative. They looked like plasma cells and they secreted only lambda light chains. Both these cells and the patient's fresh cells were hypodiploid and contained the Philadelphia chromosome and several other markers. This line seems to be the first human plasmacytoma line since the IgE lambda-producing line (U266) established in 1968, and it may be suitable for the production of human monoclonal antibodies.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6122771     DOI: 10.1016/s0140-6736(82)91933-x

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  4 in total

1.  A human myeloma cell line suitable for the generation of human monoclonal antibodies.

Authors:  A Karpas; A Dremucheva; B H Czepulkowski
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-13       Impact factor: 11.205

Review 2.  Human monoclonal antibodies.

Authors:  S P Cole; B G Campling; T Atlaw; D Kozbor; J C Roder
Journal:  Mol Cell Biochem       Date:  1984-06       Impact factor: 3.396

3.  Two new IgA1-kappa plasma cell leukaemia cell lines (JJN-1 & JJN-2) which proliferate in response to B cell stimulatory factor 2.

Authors:  N Jackson; J Lowe; J Ball; E Bromidge; N R Ling; S Larkins; M J Griffith; I M Franklin
Journal:  Clin Exp Immunol       Date:  1989-01       Impact factor: 4.330

Review 4.  Human monoclonal antibodies: methods of production and some aspects of their application in oncology.

Authors:  L Olsson
Journal:  Med Oncol Tumor Pharmacother       Date:  1984
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.